Journal article Open Access

Re-Purification of ALK2 for crystallisation with different compounds from M4K.

Williams, E.P.; Bullock, A.N.

Dublin Core Export

<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="" xmlns:oai_dc="" xmlns:xsi="" xsi:schemaLocation="">
  <dc:creator>Williams, E.P.</dc:creator>
  <dc:creator>Bullock, A.N.</dc:creator>
  <dc:description>Cleaning up of a frozen purified sample of ALK2/ACVR1 by gel filtration after thawing for use in co-crystallisation trials with five M4K compounds (M4K2163, M4K2143, M4K2192, M4K2207 and M4K2194). You can read more about it on Open Lab Notebooks.</dc:description>
  <dc:description>Funding Acknowledgment: The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.</dc:description>
  <dc:subject>M4K Pharma</dc:subject>
  <dc:title>Re-Purification of ALK2 for crystallisation with different compounds from M4K.</dc:title>
All versions This version
Views 112112
Downloads 2727
Data volume 12.5 MB12.5 MB
Unique views 9494
Unique downloads 2424


Cite as